STERLING GREEN GROUP PLC

Inactive Instrument

Analyst Reco. Sterling Green Group PLC London S.E.

Equities

GB00B1N0T068

End-of-day quote London S.E. Other stock markets
- ^GBX	-

2023	Amryt Pharma plc(NasdaqGS:AMYT) dropped from S&P Global BMI Index	CI
2023	Amryt Pharma plc(NasdaqGS:AMYT) dropped from NASDAQ Composite Index	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

HC Wainwright Downgrades Amryt Pharma to Neutral From Buy, Cuts Price Target to $14.50 From $18	23-01-18	MT
Maxim Group Downgrades Amryt Pharma to Hold From Buy	23-01-10	MT
Cantor Fitzgerald Downgrades Amryt Pharma to Neutral From Overweight, Adjusts Price Target to $14.75 From $25	23-01-10	MT
Canaccord Genuity Downgrades Amryt Pharma to Hold From Buy, Adjusts Price Target to $17 From $19	23-01-10	MT
Canaccord Genuity Assumes Amryt Pharma at Buy Rating With $19 Price Target	22-09-06	MT
SVB Securities Adjusts Amryt Pharma's Price Target to $19 From $18, Keeps Outperform Rating	22-06-24	MT
SVB Leerink Adjusts Amryt Pharma's Price Target to $18 from $10, Keeps Outperform Rating	22-05-05	MT
SVB Leerink Adjusts Amryt Pharma's Price Target to $10 from $9, Keeps Outperform Rating	22-03-10	MT
HC Wainwright Adjusts Amryt Pharma's Price Target to $18 From $20, Maintains Buy Rating	22-03-10	MT
HC Wainwright Adjusts Amryt Pharma's Price Target to $20 From $29, Reiterates Buy Rating	22-03-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer